Navigation Links
Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
Date:5/15/2008

BALTIMORE, May 15 /PRNewswire/ -- Lentigen Corporation announced today that it has received four National Institutes of Health (NIH) small business innovation research (SBIR) grants to collaborate with leading scientists. Through these grants, Lentigen will apply its proprietary lentiviral vector (LV) technology to the development of novel immunotherapeutic treatments for diseases of high unmet medical need:

-- Melanoma, with Michael Nishimura, Ph.D, Associate Professor of Surgery,

Medical University of South Carolina

-- Hepatitis C virus (HCV) infection, also with Dr. Nishimura

-- Epstein-Barr virus (EBV)-related diseases, with Adrian Wiestner,

M.D./Ph.D., Principal Investigator, National Cancer Institute

-- Chronic lymphocytic leukemia (CLL), also with Dr. Wiestner

Together with its collaborators, Lentigen will develop lentiviral vectors designed to target specific cells related to each of these diseases. For melanoma, HCV, and EBV, the vectors will transduce T cells, which play a central role in cell-mediated immunity, with proteins known as T cell receptors (TCRs) that have been engineered to attack the targeted disease. For CLL, the vectors will carry weakened cells of this cancer combined with other substances designed to trigger an immune response.

"These innovation research grants are enabling us to extend the application of our lentiviral vector technology to a wider range of diseases while working with distinguished researchers to address the urgent need for novel biotherapeutics and vaccines in areas of high unmet medical need," said Tim Ravenscroft, Lentigen's CEO.

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine and research applications in biotechnology and medicine. Lentiviral vectors are the most efficient vehicles for the deli
'/>"/>

SOURCE Lentigen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
2. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
3. Lentigen to Move Headquarters and Manufacturing to Gaithersburg
4. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
5. VIRxSYS and Lentigen Announce Litigation Settlement
6. Baxa Corporation Wins Two Colorado BMA 2008 Gold Key Awards
7. Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Triple-S Management Corporation Appoints New Non-Executive Chairman to Board; Adds New Director
9. Genaera Corporation Announces First Quarter Financial Results
10. EUSA Pharma Completes Acquisition Of Cytogen Corporation
11. Pharmos Corporation Reports 2008 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 According to ... (Consumables, Instruments, Services), Methods (Phenotypic, Genotypic), Applications (Pharmaceutical, Diagnostic, ... Characterization) - Global Forecasts to 2019" published ... estimated at $896.5 Million in 2014 and ... 2019, growing at a CAGR of 5.9% ...
(Date:7/28/2014)... 28, 2014   Propeller Health , the FDA-cleared ... hire of Brad Towle as Senior Vice ... for driving the company,s sales growth, customer acquisition and ... and specifically his past role in the development of ... at this pivotal time in the industry," said ...
(Date:7/28/2014)... Francisco, California (PRWEB) July 28, 2014 ... USD 604.40 billion by 2020, according to a new ... coupled with the rising demand for effective vaccines and ... patients with unmet medical needs is expected to drive ... the need to enhance agricultural productivity via the use ...
(Date:7/28/2014)... Research and Markets has announced the ... report to their offering. ... technique used to determine the size of a particle in ... to analyze the size of particles as it can affect ... performed to determine the behavior and nature of a material, ...
Breaking Biology Technology:Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4Global Particle Size Analysis Market 2014-2018 2
... (Nasdaq: SIAL ) is pleased to announce ... Chief Information Officer, effective August 16, 2010. In his ... systems function and will report to Rakesh Sachdev, Sr. ... Borg (age 50) brings over two decades ...
... Unaudited Second Quarter Results -- re> SHENYANG, China, Aug. 17 /PRNewswire-Asia-FirstCall/ -- ... ... ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Statement re ProAmatine -- PHILADELPHIA, Pennsylvania, August 17, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Biology Technology:Sigma-Aldrich Announces Appointment of Magnus Borg as Vice President and Chief Information Officer (CIO) 23SBio Inc. Announces Unaudited Second Quarter Results 23SBio Inc. Announces Unaudited Second Quarter Results 33SBio Inc. Announces Unaudited Second Quarter Results 43SBio Inc. Announces Unaudited Second Quarter Results 53SBio Inc. Announces Unaudited Second Quarter Results 63SBio Inc. Announces Unaudited Second Quarter Results 73SBio Inc. Announces Unaudited Second Quarter Results 83SBio Inc. Announces Unaudited Second Quarter Results 93SBio Inc. Announces Unaudited Second Quarter Results 103SBio Inc. Announces Unaudited Second Quarter Results 113SBio Inc. Announces Unaudited Second Quarter Results 123SBio Inc. Announces Unaudited Second Quarter Results 133SBio Inc. Announces Unaudited Second Quarter Results 143SBio Inc. Announces Unaudited Second Quarter Results 153SBio Inc. Announces Unaudited Second Quarter Results 163SBio Inc. Announces Unaudited Second Quarter Results 173SBio Inc. Announces Unaudited Second Quarter Results 183SBio Inc. Announces Unaudited Second Quarter Results 19Shire plc - Statement re ProAmatine 2Shire plc - Statement re ProAmatine 3Shire plc - Statement re ProAmatine 4Shire plc - Statement re ProAmatine 5Shire plc - Statement re ProAmatine 6
(Date:7/29/2014)... PARIS, 29 JULY 2014 With thirty days to ... for the FEBS-EMBO 2014 Conference are well underway. The ... Biochemical Societies (FEBS), EMBO, and the French Society for ... Saturday, 30 August to Thursday, 4 September at the ... 2014 Conference is the largest meeting for the life ...
(Date:7/29/2014)... it affects 1 in 100,000 people characterized by a ... cause remains unknown, a new study by a team of ... in Germany and other European institutions confirms for the first ... on 6 July in Nature Genetics , is an ... swallow, a sphincter in the lower esophagus opens, allowing food ...
(Date:7/28/2014)... drugs already approved by the U.S. Food and Drug ... growth of certain bacterial pathogens inside human cells, including ... fever. The findings, published in mBio , the ... demonstrate a new way of identifying non-antibiotic drugs that ... A handful of drugs on the list inhibit the ...
Breaking Biology News(10 mins):Counting down to FEBS-EMBO 2014 in Paris, France 2Mysterious esophagus disease is autoimmune after all 2New route to identify drugs that can fight bacterial infections 2
... was launched today by the Chinese National Space Administration ... Centre, Sichuan, atop a Long March 3A rocket. ... to land robotic explorers on the Moon before 2020. ... first is to make three-dimensional images of many lunar ...
... and Ludwigshafen, Germany-October 24, 2007-Harvard University,s Office of ... agreement to jointly establish the BASF Advanced Research ... of Engineering and Applied Sciences (SEAS) the initiative ... and schools throughout the University. Set up ...
... Researchers at the University of Minnesotas Stem Cell Institute ... used to study how human embryonic stem cells differentiate. ... Experimental Biology and Medicine. Researchers know very little ... fully understand these cells self renewal capacity and pluripotency, ...
Cached Biology News:Chang'e-1 -- new mission to Moon lifts off 2BASF and Harvard University announce extensive research collaboration 2